Has Sophie Deng, MD received payments from drug or device companies?

Yes. Drug and device makers reported $51,743 in general payments to Sophie Deng, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sophie Deng, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sophie Deng, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sophie Deng, MD

Ophthalmology · Los Angeles, CANPI 1194775890

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $40,341 of the $51,743 with a category attached, or 78.0%. 10 manufacturers reported payments, led by Amgen at 56.7% of the total. Reporting peaked in 2023 at $28,149 and has fallen 82.1% since, to $5,050 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,743in general payments, 2019–2025

Across 29 payments — averaging $1784.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$29K
Dompe US, Inc.$6K
Alcon Research LLC$6K
Kowa Research Institute, Inc.$4K
Kala Pharmaceuticals, Inc.$3K
W. L. Gore & Associates, Inc.$2K
plus $2K from 4 others

$33,730in research payments, 2019–2025

Across 13 payments — averaging $2594.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Kowa Research Institute, Inc.$34K

What the payments were for

Consulting fees$40,34178%
Speaking & faculty fees$9,10018%
Travel & lodging$1,6183%
Food & beverage$6841%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	3	$29,341
Dompe US, Inc.	10	$6,067
Alcon Research LLC	2	$5,790
Kowa Research Institute, Inc.	3	$3,725
Kala Pharmaceuticals, Inc.	2	$3,000
W. L. Gore & Associates, Inc.	1	$1,500
Oyster Point Pharma, Inc.	2	$1,198
Alcon	3	$601
KOWA Company, LTD.	2	$372
Carl Zeiss Meditec USA, Inc.	1	$149

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,743 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California →

Medicare billing

Part B allowed, 2024

$184,378

Medicare patients

287

Services billed

1,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RestasisCyclosporine	42	$25,034
XiidraLifitegrast	28	$19,115
Prednisolone Acetate	498	$16,499
CequaCyclosporine	21	$15,478
Cyclosporine	25	$9,004
NatacynNatamycin	13	$7,332
ZirganGanciclovir	13	$5,748
RhopressaNetarsudil Mesylate	16	$5,715
Difluprednate	68	$5,322
MoxifloxacinMoxifloxacin Hcl	181	$3,705
Dorzolamide-TimololDorzolamide/Timolol/Pf	23	$2,951
Brimonidine Tartrate	43	$2,269
ValacyclovirValacyclovir Hcl	22	$1,057
ErythromycinErythromycin Base	67	$630
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	37	$412

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Los Angeles

Andrew MoshfeghiLos Angeles$895K
Barry SeibelLos Angeles$835K
Nicole FramLos Angeles$551K
Neda ShamieLos Angeles$547K
David BoyerLos Angeles$406K
David HamiltonLos Angeles$359K
Arjan HuraLos Angeles$306K
Firas RahhalLos Angeles$264K
Kouros NourimahdaviLos Angeles$258K
Daniel RootmanLos Angeles$247K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →